Navigation

Breast cancer (advanced) - eribulin [ID359]

Eribulin for the treatment of locally advanced or metastatic breast cancer

Status: History
Expected date of issue: December 2011
Referral date: September 2010
Process: STA
Notes:

Scoped within Batch 13

Topic area:
  • Cancer
 

NICE project team

Executive Lead: Andrew Dillon
Technical Lead: Raisa Sidhu
Communications manager: Alice Law
Project manager: Kate Moore
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 11 March 2011
1st appraisal committee meeting: 23 June 2011
2nd appraisal committee meeting 27 September 2011
Top


 

Consultees and commentators

Consultees

 

Commentators (no right to submit or appeal)

 

Manufacturers/sponsors

  • Eisai (eribulin)

Patient/carer groups

  • Breakthrough Breast Cancer
  • Breast Cancer Campaign
  • Breast Cancer Care
  • Macmillan Cancer Support

Professional groups

  • Cancer Research UK
  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians

Others

  • Department of Health
  • NHS Camden
  • Welsh Government

General

  • British National Formulary
  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Health Improvement Scotland

Comparator manufacturers

  • Actavis (vinorelbine) (CA&U not returned, not participating)
  • Hospira (vinorelbine) (CA&U not returned, not participating)
  • Medac UK (vinorelbine) (CA&U not returned, not participating)
  • Pierre Fabre (vinorelbine)
  • Roche Products (capecitabine)
  • Wockhardt (vinorelbine) (CA&U not returned, not participating)

Relevant research groups

  • National Cancer Research Institute

Evidence Review Group

  • Liverpool Reviews & Implementation Group, University of Liverpool
  • National Institute for Health Research Health Technology Assessment Programme

Associated guideline groups

  • None

Associated public health groups

  • None

Top


 

Project history

Date Update
24 August 2011 We have been able to confirm with the manufacturer a date for submission of the additional analyses and commission the Evidence Review Group to look at this new information. Therefore, we have been able to schedule the second discussion of this topic into the 27 September 2011 committee meeting.
12 August 2011 The manufacturer of eribulin, Eisai, has requested to submit additional analyses in relation to the appraisal of eribulin for the treatment of locally advanced or metastatic breast cancer. This request has been considered by the Centre Director, who has agreed to accept this new evidence. Therefore, the second committee meeting discussion originally planned for 25 August 2011 has now been postponed to enable the manufacturer to submit the additional analyses and to commission an evidence review of the new analyses.

We will update as soon as possible with the confirmed timelines for the next committee meeting.
Top


 

Key documents

This page was last updated: 01 April 2012

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.